Skip to main content

JAMA - Update/Review of Hemochromatosis Dx and Rx. - 5 gene defects in hepcidin. 95% HFE & the C282Y variant - 90%ar

Social Author Name
Dr. John Cush
Tweet Content
JAMA - Update/Review of Hemochromatosis Dx and Rx. - 5 gene defects in hepcidin. 95% HFE & the C282Y variant - 90%are asymptomatic - Suspicion w/ arthralgias, LFTs, hepatomegaly, cardiomyopathy, 1st degr relative - Untreated, 9% risk of cirrhosis https://t.co/CVDbXtqOBw https://t.co/R4ed2FNxdh

Study of 294 SLE pts on HCQ (2005-2021): 37 (13%) developed CHF w/ low EF (HFrEF), arrhythmia or cardiac death. After a

Social Author Name
Dr. John Cush
Tweet Content
Study of 294 SLE pts on HCQ (2005-2021): 37 (13%) developed CHF w/ low EF (HFrEF), arrhythmia or cardiac death. After adjustments, wt-based dosing of HCQ not assoc w/ cardiac events(sHR 0.62; 0.41,0.92) & may decrease risk in non-smokers https://t.co/Qyp2odOfpj https://t.co/Q1qdv0CQ5P

Tyk2 Inhibition Effective in SLE Deucravacitinib, an oral, selective TYK2 inhibitor, has demonstrated efficacy in a ph

Social Author Name
Dr. John Cush
Tweet Content
Tyk2 Inhibition Effective in SLE Deucravacitinib, an oral, selective TYK2 inhibitor, has demonstrated efficacy in a phase II trial active systemic lupus erythematosus (SLE) patients. https://t.co/6pqRZO2VNA https://t.co/iJfhyRs8nw

The spicy topic of turmeric in RA Curcumin has increasingly been promoted as a potential RA therapy, but data presented

Social Author Name
Dr. John Cush
Tweet Content
The spicy topic of turmeric in RA Curcumin has increasingly been promoted as a potential RA therapy, but data presented at #ACR22 suggests it is unable to do any better than placebo in replacing conventional rheumatoid arthritis therapies. https://t.co/C0O0DyXn34 https://t.co/kv3dw476dT

Dual target blockade may be better than one in SLE Inhibition of B-cell Activating Factor (BAFF) has revolutionised th

Social Author Name
Dr. John Cush
Tweet Content
Dual target blockade may be better than one in SLE Inhibition of B-cell Activating Factor (BAFF) has revolutionised the treatment of patients with systemic lupus erythematosus (SLE). https://t.co/uu6ygb4l8B https://t.co/nLO3oSiEVa
Subscribe to
×